SkinJect™, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also ...
Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
A Metropolitan Transportation Authority rendering shows a conceptual interior of a future Second Avenue Subway station in Harlem, illustrating platform circulation, train clearances and passenger flow ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A novel GLP-1 and amylin receptor agonist reduced HbA1c ...
Cidara Therapeutics soared 250% after strong Phase 2b NAVIGATE trial results for CD388, a novel antiviral for flu prophylaxis. CD388 demonstrated up to 76% efficacy, outperforming many traditional flu ...
Equinor ASA, Shell PLC and TotalEnergies SE have approved the second phase of the Northern Lights carbon, capture and storage (CCS) project in Norway with a NOK 7.5 billion ($700 million) investment.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results